{
  "ticker": "ALA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964891",
  "id": "02964891",
  "pages": 35,
  "price_sensitive": false,
  "date": "20250702",
  "time": "0912",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lch30mtb4xsc.pdf",
  "summary": "**Summary of ASX Announcement: Investor Presentation**  \n- **Document Type**: Non-deal roadshow presentation (no material new information disclosed).  \n- **Key Highlights from Presentation**:  \n  - **Lead Product (ALA-101)**: CAR19-iNKT cell therapy for CD19+ blood cancers; Phase 1 trials expected early 2026.  \n  - **Cash Balance (31 Mar 2025)**: $23.5M.  \n  - **Manufacturing Progress**: GMP process completed for ALA-101; clinical batches in development.  \n  - **Pipeline Expansion**:  \n    - CLDN18.2-targeting CAR for solid tumours (gastric/pancreatic cancers).  \n    - IL-12-TM \"armouring\" technology to enhance efficacy (preclinical phase).  \n  - **Upcoming Milestones**: IND submission for ALA-101 (CY2025), Phase 1 data (early 2026).  \n  - **Market Context**: Recent cell therapy transactions cited (e.g., $2.1B acquisition of Capstan Therapeutics).  \n\n**No material trading or capital actions announced**. Focus on strategic updates and pipeline progression.",
  "usage": {
    "prompt_tokens": 8697,
    "completion_tokens": 245,
    "total_tokens": 8942,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-01T23:15:44.319737"
}